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Could Obstructive Sleep Apnea Syndrome be a
Component of Metabolic Syndrome?
Aim: Obstructive sleep apnea syndrome (OSAS) is a prevalent disorder and is associated with increased
cardiovascular morbidity and mortality. OSAS is independently related to the cardiovascular risk factors that
comprise metabolic syndrome, atherosclerosis, acute coronary syndrome, and sudden death. The prevalence
of metabolic syndrome is 30%-40% in the Turkish population. However, there are no data about the
prevalence of metabolic syndrome (MS) in Turkish patients with OSAS. The aim of this study was to determine
the prevalence of MS in Turkish patients with OSAS and MS-related cardiovascular diseases.
Materials and Methods: The medical records of patients who were admitted to our Sleep Disorders Center
were evaluated retrospectively. OSAS was diagnosed by polysomnography (apnea-hypopnea index (AHI) ≥ 5).
MS was diagnosed according to Adult Treatment Panel III. Individuals in whom AHI < 15 were recruited as
group 1 and those in whom AHI ≥15 as group 2.
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Results: We studied 277 patients with OSAS (206 men and 71 women, aged 52.8 ± 9.8 years). The
prevalence of MS in patients with OSAS was 39.71% (110 patients). This prevalence is higher than that in the
Turkish population. The prevalence of MS in groups 1 and 2 was 25.5% and 74.5%, respectively (P < 0.005).
Rates of MS were higher in patients with AHI ≥ 15 than in those with AHI < 15. In addition, the prevalence
of hypertension, arrhythmia, atherosclerotic heart disease, and stroke in patients with and without MS was
73.5% and 26% (P = 0.00), 10.2% and 8.5% (P = 0.41), 42.5% and 18.3% (P = 0.00), and 3% and
0.06% (P = 0.23), respectively.
Conclusions: The prevalence of MS is high in OSAS patients. In addition, the prevalence of MS is significantly
high in patients with moderate-severe OSAS.
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Obstrüktif Uyku Apne Sendromu Metabolik Sendromun Bir Komponenti
Olabilir mi?
Amaç: Obstrüktif uyku apne sendromu (OSAS), kardiyovasküler morbidite ve mortalitenin belirgin artış
gösterdiği; metabolik sendrom (MS), ateroskleroz, akut koroner sendrom ve ani ölüm ile seyreden sistemik
hastalıkların birbirine eklendiği, genel populasyonda yaygın görülen bir hastalıktır. Türk popülasyonunda MS
sıklığı % 30 – 40 olarak bulunmuştur. Ancak OSAS’lı hastalarda MS sıklığı bilinmemektedir. Bu çalışmada
amaç; uyku bozuklukları merkezimize başvuran ve polisomnografik inceleme ile OSAS tanısı alan hastalarda
MS ve MS ile ilişkili kardiyovasküler hastalıkların görülme sıklığını belirlemektedir.
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Yöntem ve Gereç: Çalışmada Uyku Bozuklukları Merkezimize başvuran hastaların kayıtları retrospektif
olarak incelendi. Tüm gece boyunca uygulanan polisomnografi (PSG) verilerine göre OSAS tanısı (ApneHipopne İndeksi=AHİ > 5) ve Adult Treatment Panel III kriterlerine göre MS tanısı alan hastalar kayıt edildi.
Hastalar orta-ağır (AHİ < 15) ve hafif (AHİ ≥ 15) olmak üzere grup 1 ve grup 2 olarak ayrıldı. Her iki grup
arasındaki MS oranı karşılaştırıldı, ayrıca hastaların demografik özellikleri kayıt edildi.
Bulgular: Çalışmaya OSAS tanısı olan toplam 277 hasta alındı. Bu hastaların 206’ sı erkek, 71’i kadın ve yaş
ortalamaları 52,8 ± 9,8 yıl idi. OSAS’lı hastalarda MS sıklığı % 39,71 (110 hasta) olarak saptandı. Grup 1’de
MS sıklığı % 25,5 ve grup 2’de % 74,5 (P < 0.005) olarak bulundu. Ayrıca kardiyovasküler hastalıklar
açısından incelendiğinde MS olan ve olmayan gruplarda hipertansiyon, aritmi, aterosklerotik kalp hastalığı ve
inme sıklığı karşılaştırıldığında sırasıyla % 73,5 - % 26 (P = 0,00), % 10,2-% 8,5 (P = 0,41), % 42,5 - %
18,3 (P = 0,00) ve % 3 - % 0,06 (P = 0,23) olarak bulundu.
Sonuç: OSAS’lı hastalarda MS görülme oranı belirgin olarak fazladır. Ayrıca AHİ değerine göre gruplandırılan
orta-ağır OSAS’lı hastalarda MS sıklığının daha fazla olduğu bulunmuştur.
Anahtar Sözcükler: Obstrüktif uyku apne sendromu, metabolik sendrom, kardiyovasküler hastalık
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Introduction
Obstructive sleep apnea syndrome (OSAS) is a
prevalent disorder particularly among middle-aged and
obese men, characterized by repeated episodes of
cessation of breathing during sleep and daytime sleepiness;
it affects approximately 5% of the adult population (1).
Recent studies showed that OSAS is associated with
increased cardiovascular and cerebrovascular morbidity
and mortality, and there is growing evidence of an
independent contribution of OSAS toward this (2,3).
Several features of OSAS suggest that sleep apnea is a part
or manifestation of metabolic syndrome (MS) (4-7). MS,
also known as insulin resistance syndrome, is known as a
cluster of obesity, glucose intolerance, dyslipidemia, and
hypertension. Previous studies have shown that there is an
independent association between OSAS and insulin
resistance and several determinants of MS including
hypertension and dyslipidemia independent of obesity (47); however, there is little information in the literature
about the prevalence of MS, which is a major risk factor
for early development of cardiovascular disease in OSAS
patients (3,5). These studies found the prevalence of MS
to be significantly high in OSAS patients compared to the
general population (1,7). Furthermore, there is no
previously published study about the prevalence of MS in
OSAS patients in the Turkish adult population, although a
recent study was conducted in children (8). The prevalence
of MS is 30%-40% in the Turkish population (9). The aim
of this study was to determine the prevalence of MS in
Turkish patients with OSAS and MS-related cardiovascular
diseases.

Materials and Methods
Patients
We enrolled 277 patients diagnosed with OSAS based
on overnight polysomnography (PSG) at the Sleep
Disorders Center at Gazi University School of Medicine
between January 2001 and December 2005. Before the
study, patients with central apnea, stroke, coronary
artery disease, congestive heart failure, intrinsic
pulmonary disease, and renal or liver disease were
excluded. We accepted a threshold apnea-hypopnea index
(AHI) ≥ 5 as diagnostic of sleep apnea.
The patients were divided into 2 groups, according to
the severity of OSAS: group 1 OSAS (AHI < 15/h) and
group 2 (AHI ≥ 15/h). Informed consent was obtained
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from all patients, the protocol was approved by the ethics
committee of Gazi University School of Medicine, and the
study was performed in accordance with the current
revision of the Declaration of Helsinki.
Clinical and Laboratory Measurements
We measured height and weight in bare feet and light
clothing in the morning. Body mass index (BMI) was
defined as weight (kg)/height2 (m). Blood pressure was
measured between 8 and 11 a.m. in the supine position
after 5 min rest.
All blood samples were obtained in the morning after
an overnight fast. C-reactive protein, fasting glucose,
total cholesterol, triglyceride, and high density lipoprotein
(HDL) cholesterol were measured after an overnight fast.
Low density lipoprotein (LDL) cholesterol was derived
using the Friedwald formula.
Definition of MS
MS was diagnosed according to the National
Cholesterol Education Program Expert Panel on
Detection, and Treatment of High Blood Cholesterol in
Adults (Adult Treatment Panel III, ATP III) criteria (10). A
diagnosis of MS was made if the patient met at least 3 of
the following criteria: 1) fasting plasma glucose ≥110
mg/dl, 2) blood pressure ≥ 130/85 mmHg or current use
of antihypertensive drugs, 3) triglycerides ≥150 mg/dl,
4) HDL cholesterol < 40 mg/dl and 50 mg/dl in men and
women, respectively. Details of waist circumference were
not available in this study.
PSG
Overnight PSG was performed in all patients using a
computerized system (Somnostar alpha; Sensormedics,
USA) on the basis of variables described previously. Sleep
parameters were determined using the criteria of
Rechtschaffen and Kahles, and arousals were defined in
accordance with the definitions of the American Sleep
Disorders Association (11,12).
Statistical analysis
Normally distributed data were presented as means ±
standard deviation of the mean (95% confidence interval
for the mean), skewed data as the median, and
categorical data as the number. Statistical analyses were
performed using SPSS version 11.0 (Chicago, IL, USA).
Unpaired t, Mann-Whitney, and chi-square tests were
used in the analyses. Significance of differences was
accepted at P < 0.05.
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Results
The demographic and clinical characteristics and
laboratory values of patients with MS and without MS are
shown in Table 1. The prevalence of MS was 39.7%
(110/277 patients). One hundred ten (39.7%) patients
presented with coexisting MS and increased BMI
(73.6%), increased serum fasting blood glucose level
(76.4%), and high blood pressure (92.7%) as the most
frequent features in men and women. All single
components were present more often in OSAS patients
with MS compared to OSAS patients without MS (Table
1). OSAS patients with MS were significantly older
compared to those without MS (P = 0.001). Risk factors
for MS did not differ between women and men. There
were no differences in drug use between OSAS patients
with and without MS.
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Of the 277 participants, 85 (31%) had AHI scores
between 5 and 15 (group 1) and 192 (69%) had AHI
scores ≥ 15 (group 2). There was a linear trend effect of
association with MS as the severity of OSAS increased in
terms of AHI. The prevalence of MS in groups 1 and 2
was 25.5% (29/85 patients) and 74.5% (81/192
patients), respectively (P = 0.035). Rates of MS were 3fold higher in OSAS patients with AHI score > 15
compared to OSAS patients with AHI score < 15.
Hypertension and atherosclerotic heart disease were also
more prevalent in OSAS patients with MS compared to
OSAS patients without MS (Table 2). A significant
relationship between a higher AHI with the increase in the
number of features of MS in the whole study group was
also demonstrated (Figure) (P < 0.05).

Table 1. Clinical parameters in all subjects with and without metabolic syndrome.
Patients with MS
(n = 110)

Patients without MS
(n = 167)

P value

52.88 ± 9.80

47.77 ± 10.19

0.001

Body mass index (kg/m )

34.27 ± 6.11

28.94 ± 4.17

0.000

Systolic blood pressure (mmHg)

145.00 ± 12.8

130.05 ± 11.5

0.006

Diastolic blood pressure (mmHg)

95.80 ± 16.50

78.07 ± 10.70

0.009

HDL-cholesterol (mg/dl)

41.62 ± 10.77

47.18 ± 10.98

0.04

Total cholesterol (mg/dl)

214.75 ± 68.40

209.00 ± 41.63

0.09

Triglyceride (mg/dl)

177.45 ± 76.13

157.11 ± 84.17

0.003

Fasting blood glucose (mg/dl)

125.36 ± 43.63

94.50 ± 8.33

0.001

39.83 ± 3.79

28.69 ± 2.22

0.005

Age (year)
2

Apnea hypopnea index (per hour)

Table 2. Cardiovascular events in OSAS patients according to the presence of metabolic syndrome (MS).
Patients with MS
(n = 110)

Patients without MS
(n = 167)

P value

Hypertension (n, %)

81, 73.5%

43, 26%

0.001

Arrhythmia (n, %)

11, 10.2%

14, 8.5%

0.41

Atherosclerotic heart disease (n, %)

47, 42.5%

31, 18.3%

0.001

3, 3%

1, 0.06%

0.23

Stroke (n, %)
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Figure. The number of components of metabolic syndrome according to
apnea-hypopnea score (AHI) in patients with obstructive sleep apnea.

Discussion
The salient findings of this study are as follows: (i) the
prevalence of MS is high in patients with OSAS, (ii) the
prevalence and components of MS including high blood
pressure, high fasting blood glucose level,
hypertriglyceridemia, and low HDL-cholesterol level
increase while the severity of OSAS increases determined
by AHI, (iii) OSAS patients with MS are more likely to
have a history of cardiovascular disease compared to
OSAS patients without MS, (iv) analysis of the MS
components shows that hypertension is the primary
variable associated with a diagnosis of OSAS. To the best
of our knowledge, this is the first study to investigate the
prevalence of MS in Turkish patients with OSAS.
The increasing recognition and acceptance of a link
between OSAS and MS, mediated through obesity, high
blood pressure, and insulin resistance, prompts the
question of whether OSAS is a component of OSAS or a
contributory factor for the development of MS. Previous
studies showed that patients with OSAS had 3- to 5-fold
higher risk of having MS and the prevalence of MS was
50%-85% in patients with OSAS (13-16). Moreover,
mortality is 3.3 times higher in OSAS patients younger
than 70 years old (17). The increase in mortality is due
to the higher rate of cardiovascular disease and accidents.
It was reported in previous studies that OSAS is
independently associated with a number of cardiovascular
and metabolic risk factors, such as hypertension,
dyslipidemia, insulin resistance, and impaired glucose
164
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tolerance. However, it is unknown whether OSAS occurs
as part of the fundamental pathophysiology of MS, or
whether OSAS, via repetitive nocturnal hypoxemia,
systemic inflammation, and other mechanisms, promotes
the components of MS (18).
In the present study, OSAS patients with MS had
higher degrees of sleep-disordered breathing such as high
AHI, low desaturation index, and minimum oxygen
saturation (Table 1). In addition, these patients had more
frequent cardiovascular comorbidity (i.e. hypertension,
arrhythmia, and atherosclerotic heart disease) than
patients without MS. Nevertheless, patients with MS had
significantly higher blood pressures, fasting glucose, and
triglyceride concentration, and reduced HDL cholesterol,
which are all components of MS (Table 1).
It is well known that respiratory disturbance
responses may increase blood pressure during apneic
events and studies reported that OSAS is an independent
risk factor for the development of hypertension (2).
Hence, it is possible that OSAS directly increases MS
incidence in these patients. In our study, the prevalence of
hypertension was significantly high in OSAS patients with
MS compared to OSAS patients without MS. There was
also a positive association between the severity of OSAS
and the presence of the components of MS, especially
hypertension.
Recent investigations have shown that OSAS is
independently associated with insulin resistance, glucose
intolerance, and increased incidence of type 2 diabetes
mellitus (19,20). These studies concluded that patients
with OSAS have higher blood pressure, higher fasting
insulin level, increased insulin resistance, lower levels of
HDL-cholesterol, and an increased incidence of MS
compared to patients without OSAS. Moreover, OSAS
patients had a higher BMI than patients without OSAS,
which raises the possibility that obesity rather than OSAS
is a primary determinant of MS (19,20). Interestingly, in
our study group OSAS patients with MS had a
significantly higher BMI as compared with OSAS patients
without MS. Thus obesity plays a pivotal role in the link
between OSAS and MS. Despite the confounding effect of
obesity, many recent studies have shown that there is an
independent association between OSAS and other
parameters of the MS, such as hypertension and insulin
resistance (4,6).
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Cardiovascular disease is the leading cause of death all
over the world and multiple risk factors are identified as
contributors, namely dyslipidemia, obesity, hypertension,
and glucose intolerance, which are also components of
MS. Many studies have reported that the presence of MS
is independently associated with an increased incidence of
all cardiovascular diseases (21,22). Hu et al. summarized
11 studies comprising more than 11,000 subjects and
found that the hazard ratio for cardiovascular mortality
was 2.26 for men and 2.78 for women in subjects with
MS compared to subjects without MS (23). In our study
we also found the prevalence of cardiovascular disease
high in OSAS patients with MS compared to OSAS
patients without MS.
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Our study has several limitations. The data were
collected retrospectively rather than prospectively.
However, we reviewed the records of consecutive
patients in the sleep laboratory and so there was no
selection bias. We did not have access to measurements
of waist circumference. Hence, the prevalence of MS
might be higher than we found in this study.
In conclusion, OSAS might be a component of MS or
an independent risk factor for development of MS and the
prevalence of MS is high in OSAS patients. Accordingly, it
seems reasonable for clinicians to include assessment of
MS in the evaluation of patients with OSAS. Further
studies are warranted to elucidate the pathogenesis of
OSAS on development of MS and the effect of treatment
of OSAS on MS.
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